MEN 10627 is the prototype of a new class of cyclic peptide-based NK-2 receptor antagonists. Owing to its high potency and long lasting activity in vivo, MEN 10627 and its analogs are suitable candidates for clinical testing in humans.
A New Potent and High Selective, Long Lasting, Peptide Based Neurokinin A Antagonist: Rational Design of MEN10627 / Pavone, Vincenzo; Lombardi, Angelina; C., Pedone; L., Quartara; C. A., Maggi. - STAMPA. - (1994), pp. 487-489.
A New Potent and High Selective, Long Lasting, Peptide Based Neurokinin A Antagonist: Rational Design of MEN10627
PAVONE, VINCENZO;LOMBARDI, ANGELINA;
1994
Abstract
MEN 10627 is the prototype of a new class of cyclic peptide-based NK-2 receptor antagonists. Owing to its high potency and long lasting activity in vivo, MEN 10627 and its analogs are suitable candidates for clinical testing in humans.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
